Shen-Qi Paste Shows Promise for Preserving Muscle in Dialysis Patients
A 12-week trial found better muscle mass with Shen-Qi Paste, but no clear mobility benefit. Safety details were missing from the abstract.
Summary
Muscle loss can undermine independence in adults receiving dialysis. In a randomized trial, 128 dialysis patients with sarcopenia received Shen-Qi Paste, a traditional Chinese herbal formulation, or placebo for 12 weeks. Both groups also performed light exercise. The paste improved a measure of muscle mass compared with placebo. Grip strength was higher relative to the placebo group, although the abstract reports that strength declined in the paste group, suggesting preservation rather than improvement. Nutrition and sleep scores also favored the paste, but chair stand performance and quality of life did not differ significantly between groups. These preliminary findings do not establish benefits for healthy adults or justify starting the formulation independently. This summary relies on the abstract only, which provides no detailed adverse event results despite the study’s stated safety objective.
Detailed Summary
Muscle loss can make everyday activities harder and threaten independence, especially in adults receiving dialysis. Treating this problem matters for healthspan because preserving muscle supports mobility and resilience. A small randomized trial tested whether Shen-Qi Paste, a traditional Chinese herbal formulation, could help dialysis patients with sarcopenia, the medical term for low muscle mass and impaired strength or performance.
Researchers at two centers randomly assigned 128 adults aged 45 to 89 to receive either the paste or a placebo for 12 weeks. Neither participants nor investigators knew the assignments. The dose was 15 grams twice daily. Both groups also performed light exercise for 20 to 30 minutes three to four days weekly. Overall, 117 participants completed the full treatment period.
Compared with placebo, the paste improved an index of muscle mass. Grip strength was also higher relative to the comparison group, although the abstract reports that strength declined in the paste group. This suggests relative preservation rather than a clear strength gain. Importantly, the groups did not differ significantly in chair stand performance, quality of life, or a questionnaire assessing frailty after the treatment period.
The paste group also showed better nutrition and sleep scores and lower inflammation and blood urea nitrogen than the placebo group. These additional findings are encouraging but do not establish improved daily functioning or longer survival. The results apply to dialysis patients with sarcopenia, not healthy adults seeking muscle gains or general antiaging benefits from supplements.
This summary is based on the abstract only, which provides no detailed adverse event results. Safety therefore remains uncertain despite appearing in the title. The short duration, modest sample, and unclear handling of dropouts also limit confidence. Larger, longer trials should confirm meaningful functional benefits and safety before this formulation becomes routine care, particularly given potential herbal medication interactions.
Key Findings
- Shen-Qi Paste improved skeletal muscle mass index versus placebo after 12 weeks in dialysis patients with sarcopenia.
- Grip strength favored the paste versus placebo, but declined within the paste group; this was not a demonstrated strength gain.
- Chair stand performance, quality of life, and frailty scores did not differ significantly between groups.
- Nutrition and sleep scores improved versus placebo, alongside lower C-reactive protein and blood urea nitrogen.
- The abstract provides no detailed adverse event results; patients should discuss this formulation with their dialysis team before considering use.
Methodology
This two-center, randomized, double-blind, placebo-controlled trial enrolled 128 dialysis patients aged 45–89 with sarcopenia. Participants received Shen-Qi Paste or placebo at 15 grams twice daily for 12 weeks, alongside the same light exercise regimen; 117 completed treatment. Primary outcomes included skeletal muscle mass index, grip strength, and five-times sit-to-stand performance.
Study Limitations
This summary is based on the abstract only, which omits detailed adverse event results, formulation ingredients, and information needed to clarify the statistical reporting. The 12-week duration, modest sample, 11 dropouts, and unclear handling of missing data limit interpretation. Numerous outcomes were tested without a reported adjustment for multiple comparisons, and the findings cannot be generalized to adults without dialysis-dependent kidney disease.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: